In relation to the successful completion of Phase I clinical trials, Shilpa Medicare Ltd has announced that the Subject ...

Shilpa Medicare Ltd announces that the results of its Phase I clinical trials were accepted by Subject Expert Committee ...

A paper published in Gravitational and Space Research unveils insights gained from International Space Station ...

The rHA 20% product, derived from yeast, is a highly purified alternative to human serum albumin, matching it structurally ...

Shilpa Medicare has informed that the subject expert committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval ...

Shilpa Medicare's Recombinant Human Albumin 20% (rHA) is derived from yeast and offers a highly purified, structurally and ...

and while plasma or serum is directly comparable between patients, the comparison of BAL is more complex. This has led to variable reporting of results using different methods of BAL correction, ...